Condition: AML (Acute Myeloid Leukemia) · BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm) · Sponsor: Chongqing Precision Biotech Co., Ltd
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
This description comes directly from the study's public registry record.
Wei Jia, Professor · +86 13986102084 · jiawei@tjh.tjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology. | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06690827